Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-65

Trying to be fair minded.

As some have suggested here, I think there is a concession in the announcement that overall all age mortality in ventilated Covid-19 ARDS patients may be less than the 60% figure MSB have suggested in recent announcements.

“Despite improved treatment and earlier intervention in hospitalised patients overall, the mortality rate in COVID-19 ARDS patients overall who are over 60 years old remains more than 60%”.

I note that the data sets in the three articles cited in the announcement to support this statement were collected up to June 18th, May 26th and April 20th respectively. Treatment could have and likely has improved since then.

Nonetheless, this data table in the first of the cited articles makes the age factor abundantly clear.



https://ehrn.org/articles/mortality-of-covid-19-admitted-patients-on-mechanical-ventilators

So if remestemcel-l was just being used as a lifesaving therapeutic of last resort, then yes, it might best be targeted at the 60+ age group.

But I think MSB are a step ahead. The recent change to trial conditions, clearly accounting for 'long covid' by monitoring lung function at 6 and 12 months, suggests to me that MSB might be accumulating a data set to support efficacy in ARDS patients regardless of age. I commend the proactive approach.

And clearly futility is not apparent at this stage.

Usual bias.

Herro